Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §6–7

Pramlintide — analytical characterisation

Chromatographic conditions, identity, related substances, presentation, reconstitution and in-use stability.

Document identifier
CEI-MN-019/6
Series
Compound monograph
Version
1.3
Published
15 Jul 2026
Last reviewed
15 Jul 2026
Next review
15 Jul 2028
Identifier
10.71829/cei.mono.19
Certainty
Moderate
Cycle
2026 Q3

§6Analytical characterisation

§6.1Chromatographic conditions

Column
C18, 4.6 × 250 mm, 5 µm
Mobile phase and gradient
A: 0.1 % trifluoroacetic acid in water; B: acetonitrile. Gradient 15–40 % B over 30 min
Detection
UV 214 nm; 275 nm weak (single Tyr, single Phe pair)
Retention
Early relative to lipidated analogues
Representative chromatographic traceIllustrative ultraviolet chromatogram at 214 nanometres showing the main peak and related substances.051015202530Retention time (minutes)Absorbance, 214 nm96.51 % area
Figure 7. Illustrative. Representative ultraviolet trace at 214 nanometres constructed by the Institute to show the relationship between a main peak, its related substances and the reported area percentage. The trace is generated from a seeded model and is not a chromatogram of any material. It is published to make the integration question concrete: the same material analysed on a shallower gradient would resolve peaks that this trace co-elutes, and would report a lower purity.

§6.2Identity by mass spectrometry

[M+3H]³⁺ at m/z ≈ 1317.5; deconvoluted average mass 3949.4 ± 2 Da. Reduction of the disulfide adds 2 Da and is diagnostic of a reduced or scrambled form.[3]

§6.3Related substances and degradation

Table 7. Related substances recorded for Pramlintide, with the process or storage route that generates each and its analytical signature.

Related substanceOriginAnalytical signature
Reduced (free-thiol) formFailed or reversed disulfide formation+2 Da; biologically inactive and a critical finding
Disulfide-scrambled dimerIntermolecular oxidationApproximately double mass; detected by size-exclusion or non-reducing electrophoresis
Des-Lys1 metabolite or process impurityTruncation−128 Da; retains activity, complicating potency interpretation
Deamidated Asn/Gln formsStorage+1 Da — this sequence contains five asparagine and two glutamine residues and is unusually deamidation-prone
Degradation routes
  • Deamidation is the dominant aqueous route given the high asparagine content
  • Disulfide scrambling and dimerisation
  • Despite the proline substitutions, aggregation remains possible at low pH

§7Presentation, reconstitution and storage

§7.1Presentation and reconstitution

Presentation
Aqueous solution in pen; lyophilised powder in research supply
Reconstitution
A 5 mg vial with 5.0 mL gives 1 mg/mL; a 60 µg dose is then 0.06 mL, that is 6 units on a U-100 syringe.
Storage, lyophilised
2–8 °C
Storage, reconstituted
2–8 °C, do not freeze
In-use period
Approved pen: 30 days at up to 30 °C after first use

The disulfide bond makes this one of the few peptides in the series for which a non-reducing versus reducing comparison is an essential identity check.

§7.2In-use stability

Applicable standards: CEI-MS-01 · CEI-MS-02 · CEI-MS-03 · CEI-MS-04 · CEI-MS-05 · CEI-MS-06. The full series is at methodological standards.

Working calculators: reconstitution and insulin-unit conversion · purity against peptide content · certificate minimum-data checker.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
  3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
  4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
  5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.